A Novel HSP90 Inhibitor SL-145 Suppresses Metastatic Triple-Negative Breast Cancer without Triggering the Heat Shock Response

SL-145 was a novel, rationally-designed C-terminal HSP90 inhibitor that induced apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling.